Category Archives: Cell Biology

Research Assistant in the Division of Science Biology, Dr. Dan Ohtan Wang job with NEW YORK UNIVERSITY ABU DHABI | 300862 – Times Higher Education

Description

The Wang Neuroepitranscriptomics Laboratory in the Division of Science, New York University Abu Dhabi, seeks to recruit a research assistant to work on projects focused on understanding RNA modification signaling pathways in the nervous system and their function in synaptic, neuronal and behavioral plasticity.

Research in the Wang Neuroepitranscriptomics laboratory focuses on the study of the neural mechanisms of dynamic RNA regulation and its role in regulating synaptic, neuronal and behavioral plasticity, using behavioral, biochemical, molecular and cell biology, fluorescence imaging, and next-generation sequencing methods. Central goals of the laboratory are the study of the neural mechanisms underlying dynamic RNA modifications upon cognitive development and decline. To achieve these objectives, research projects rely on genetically engineered mice models, behavioral analysis, molecular dissection, high-throughput sequencing, and cell biological approaches. Responsibilities of the research assistant include conducting literature reviews, maintaining colonies of laboratory mice, conducting behavioral and imaging data, programming experiments and data analysis routines, and training new lab members. The research assistant will also assist in drafting research reports for dissemination of research findings.

Applicants with a strong interest in understanding experience-driven gene-expression changes in neurons, good organization skills and communication skills are encouraged to apply. Candidates must hold a Bachelors/ Master's degree in Science or equivalent and prior experience in a lab setting. The ideal candidate will have basic programming experience with MATLAB, experience with genetically engineered mice and RNA sequencing data, and a background in experimental psychology or neuroscience. Organizational skills and attention to detail are essential.

The terms of employment are very competitive and include housing and transportation allowances. Applications will be accepted immediately and candidates will be considered until the position is filled. To be considered, all applicants must submit a resume, cover letter, statement of past research activities, transcript and contact information for at least two references, all in pdf format. If you have any questions, please emailok2108@nyu.edu(Dan Ohtan Wang, laboratory PI).

About NYUAD

NYU Abu Dhabi is a degree-granting research university with a fully integrated liberal arts and science undergraduate program in the Arts, Sciences, Social Sciences, Humanities, and Engineering. NYU Abu Dhabi, NYU New York, and NYU Shanghai, form the backbone of NYUs global network university, an interconnected network of portal campuses and academic centers across six continents that enable seamless international mobility of students and faculty in their pursuit of academic and scholarly activity. This global university represents a transformative shift in higher education, one in which the intellectual and creative endeavors of academia are shaped and examined through an international and multicultural perspective. As a major intellectual hub at the crossroads of the Arab world, NYUAD serves as a center for scholarly thought, advanced research, knowledge creation, and sharing, through its academic, research, and creative activities.

EOE/AA/Minorities/Females/Vet/Disabled/Sexual Orientation/Gender Identity Employer

UAE Nationals are encouraged to apply.

Equal Employment Opportunity Statement

For people in the EU, click here for information on your privacy rights under GDPR:www.nyu.edu/it/gdpr

NYU is an equal opportunity employer committed to equity, diversity, and social inclusion.

Link:
Research Assistant in the Division of Science Biology, Dr. Dan Ohtan Wang job with NEW YORK UNIVERSITY ABU DHABI | 300862 - Times Higher Education

Rutgers Scientist Who Researches the Sense of Smell Named Rita Allen Foundation Scholar – Rutgers University

Kevin Monahan will use award to extend his research into spinal cord injuries

Before the COVID-19 pandemic when losing the sense of smell and taste became a common sign of infection Kevin Monahan says most people took smell for granted.

Smell has really been underappreciated, said Monahan, an assistant professor in the Department of Molecular Biology and Biochemistry in the School of Arts and Sciences at Rutgers University-New Brunswick. His research into our sense of smell earned him recognition as a 2022 Rita Allen Foundation Scholar.

It was not the focus of our attention like hearing and vision until COVID took the sense of smell and taste away from people and they realized how important it was to them, he said.

He is one of five scholars to earn this years award for early-career leaders in biomedical sciences whose research holds exceptional promise for revealing new pathways to advance human health. He joins a distinguished group of honorees who have made fundamental contributions to their fields and historically gone on to earn some of the most prestigious honors including the Nobel prize.

Monahan understands the importance of smell: the aroma of fresh-baked brownies that can bring back a pleasant childhood memory or the stink of garbage on a New York City Street that will turn the same nose up in disgust. He has spent years researching smell on the molecular level.

At Rutgers, the Monahan Lab studies just how the olfactory system or sense of smell can identify so many different scents, about one trillion for humans who have about 10 million nerve cells in their nose and 400 dedicated sense of smell genes.

While this biological interaction allows humans to smell pleasant and not-so-pleasant odors, each neuron has only one receptor that signals to the brain to identify whether it was stimulated by the smell of freshly mown grass or freshly brewed coffee.

Monahans research recognized by the Allen Foundation focuses on these specialized sensory cells high inside the nose that send messages to the brain to identify smell. Working with mice, his aim is to decipher the regulatory mechanism to determine how one gene is selected to stimulate the smell.

It gets really complicated because there are hundreds of different receptors and they are in one part of the nose, not the other, Monahan said.There are many complexities that we are just beginning to understand.

Monahans team is not only trying to identify the mechanism that makes this gene expression occur to understand the sense of smell on a molecular level more clearly, but to also to examine the implications the research may have on the nervous system in general.

Ive always been interested in understanding the diversity of cell types, the specialized cells that make the nervous system work and how you turn on the right genes to generate a different outcome, Monahan said.

He and the four other scholars from Harvard, Stanford, Columbia and Brown universities will receive grants of up to $110,000 annually for five years. They have been selected to conduct innovative research on critical topics in cancer, immunology and neuroscience.

The funding will be used to continue his research on how 3D DNA structures in the nucleus of cells impact gene regulation, while developing novel molecular tools to understand and analyze brain circuits and investigate the evolution of the cerebral cortex. The cerebral cortex is responsible for language, memory, reasoning, thought, learning, decision-making, intelligence and personality.

Monahan says the funding from the Allen grant will enable him to build on what he has learned about how the brain works regarding the sense of smell and take his research on gene regulation in a new direction.

He plans to work with Victoria Abraira, an assistant professor of cell biology and neuroscience in the School of Arts and Sciences, who studies mice to understand what happens to the human spinal cord after injury, and whether the chronic pain state can change the nuclear structure of a cell.

My lab is really interested in how different types of cells in the nervous system respond to the environment, said Monahan. We want to know how does an injury with chronic pain change the neurons. To deal with these injuries, we need to have a better understanding of the cells in your spinal cord to determine what is going wrong and what needs to be done to fix it.

Read the original here:
Rutgers Scientist Who Researches the Sense of Smell Named Rita Allen Foundation Scholar - Rutgers University

Science Talk – What is discovery science? – The Institute of Cancer Research, London – The Institute of Cancer Research

Frequently overshadowed by clinical research, discovery science in the laboratory might sometimes seem to be hidden behind the scenes. But this research is crucial in the fight against cancer and at The Institute of Cancer Research we are determined to shine a spotlight upon discovery science.

Cancer discovery science is research that aims to transform our fundamental understanding of cancer biology. It is sometimes called basic or fundamental science (although its usually very complicated!). Discovery science investigates a huge range of topics within cancer biology ranging from the process involved in the regulation of cell division to how cancer can evolve and adapt, from the immune systems interactions with cancer cells to the role of chemical signal networks in cancerous cell growth.

Discovery science is often done on cells or in model systems, such as yeast, fruit flies, nematode worms and mice, where scientists try to recreate the cancers found in the human body. It also includes computational science which uses mathematical models to analyse and answer scientific questions.

Conclusions from discovery science can then, with further research, be used to translate the findings into results that directly benefit people: a process often described as going from bench to bedside.

Although their work is some way off from the clinic, discovery scientists at the ICR are determined to choose areas of research that have the potential to ultimately benefit patients. They focus on finding clues from fundamental cancer biology that might lead to the development of promising, innovative new cancer treatments.

The ICR has hundreds of discovery science researchers, I spoke to some of them about their work and why they think discovery science deserves to be celebrated.

Professor Jon Pines is Head of the Division of Cancer Biologyat the ICR. As a PhD student Professor Pines worked in the lab of Nobel Prize laureate Sir Tim Huntat the University of Cambridge. Jon contributed to the discovery science research on cyclins (proteins involved in the control of cell division cycles) in sea urchin eggs which earned Hunt the 2001 Nobel Prize in Physiology or Medicinealongside Sir Paul Nurseand Leland H. Hartwell.

There is nothing quite like discovering the answer to something in science and a brief moment realising that you are the only person in the world who knows it. Professor Pines says. I had that feeling when I cloned and sequenced cyclin in Tims lab.

The discovery that cyclins are key regulators of cell growth and division allowed cancer researchers to explore whether the inhibition of protein complexes containing cyclins, called cyclin-dependent kinases(CDKs), might have potential as a cancer treatment. One of these CDK inhibitors, palbociclib, is now a common treatment for some types of breast cancer.

Without the discovery science done by Tim Hunt and others we wouldnt have palbociclib. The origins of every drug discovery can be traced to discovery research and that, for me, is the reason that we should be celebrating discovery science.

It might be hard to see how studying animals like sea urchins can tell us anything about cancers in humans. I asked Dr Lucas Dent, Postdoctoral Training Fellow in the Dynamical Cell Systems Labat the ICR, about the importance of cell and animal models in discovery science.

One way to understand the intricate mechanisms going on within and between cells is to first look at cells isolated in the lab and simple life forms. Dr Dent explained, These model organisms have very similar basic biology to humans and can provide clues to how cancer works in humans. It is also possible to genetically modify a lot of model organisms to investigate the role of certain genes and proteins.

In our lab we genetically modify fruit flies, as well as using computational methods, and human cells, to understand more about how complex biochemical signalling networks are rewired during the development of cancer.

He continued, However, its important to be clear that findings in discovery science are a starting point in the process, when considering future patient benefit. Cells can behave differently when isolated in the lab and within animals that are not closely related to humans. So, discovery science findings should be viewed as pieces of a puzzle, it takes a lot of puzzle pieces coming together before we see the picture.

Another great example of discovery science leading to a vital new treatment for patients is the work by ICR scientists on characterising the BRAF geneand its role in cancer.

In the early 1990s, a team of ICR researchers led by Professor Chris Marshallbegan studying a cell signalling pathway involved in the control of cell growth. Their research looked at the role of the pathway known as the RAS/RAF/MEK pathway in cancer. Further work by the team suggested that a protein called BRAF might contribute to cancer development.

The researchers then went on to confirm mutated BRAF as an oncogene capable of driving the development of cancer even in the absence of other major genetic defects.

These findings from discovery science research helped pharmaceutical companies discover cancer drugs which act by inhibiting the mutated BRAF protein. These selective inhibitors of mutated BRAF include dabrafenibwhich has been approved to treat melanoma skin cancer.

Professor Jon Pines, who has the title of the Chris Marshall Chair of Cell Biology at the ICR, spoke to me about this work. Chris worked at the ICR for 35 years, he was an extremely insightful and rigorous scientist. Its fantastic to be able to trace his discovery in the lab and see it go all the way to the point where it has a positive effect on the lives of patients.

Professor Pines continued, There are few organisations where you can see the research go from lab bench to patient bedside as you do at ICR, and thats pretty special.

Dabrafenib was discovered by a GlaxoSmithKlineteam which included Dr Olivia Rossanese who is now Head of the Division of Cancer Therapeuticsand Director of the Cancer Therapeutics Unitat the ICR. Dr Rossanese agrees that discovery science is essential to drug discovery and development.

Whats really important for us is to understand the underlying mechanisms and genetic alterations in cancer that lead to uncontrolled tumour growth and spread. she explains, And when we begin to understand those mechanisms, we really have a good idea of what the targets are for therapeutics.

The discovery science research into the RAS/RAF/MEK pathway by Professor Marshall and others at the ICR also led to identification of the mechanism by which mutated RAS proteins cause cells to become cancerous.

The team showed that the RAS protein activates an important signalling pathway in cells called the MAP kinase pathway. In cancer cells with a mutated RAS the MAP kinase pathway is always switched on and drives cancers to grow.

Further research found that two molecules, RAF and MEK, transmit signals from RAS to MAP kinase and are essential to cancer growth. RAF and MEK are excellent drug targets and translational research based on the ICRs fundamental science led to the discovery of the MEK inhibitor trametinib. Trametinib is now licensed for use and regularly used alongside dabrafenibto treat melanoma.

Someone who has directly benefited from the science at the ICR which led to the discovery of dabrafenib and trametinib is patient advocate Debbie Keynes.

Debbie was diagnosed with advanced melanoma in April 2016 and was treated with dabrafenib and trametinib for a number of years.

We spoke to Debbie in 2018 and she told us about her experience of being diagnosed with melanoma and her treatment with dabrafenib and trametinib.

At the ICR we are extremely proud of our discovery science research. I spoke to the Chief Executive and President of the ICR, Professor Kristian Helin, about why this part of our research is so key.

Take the Covid-19 vaccines for example, what most people dont realise is that there will have been at least 25 years of discovery research in labs which enabled the vaccines to be developed and taken to clinical trialsso quickly. Without discovery science we would not have vaccines, its that simple.

For cancer its the same there would be no new drugs if it wasnt for discovery science. Its an absolutely fundamental part of the work we do at the ICR.

Go here to read the rest:
Science Talk - What is discovery science? - The Institute of Cancer Research, London - The Institute of Cancer Research

Endpoints News Expands Editorial Team With Appointments of Jared Whitlock and Aayushi Pratap – Business Wire

LAWRENCE, Kan.--(BUSINESS WIRE)--Endpoints News, the biopharma industrys leading source for daily news and analysis, announced today the expansion of its editorial team with the appointments of Jared Whitlock as Features Editor and Aayushi Pratap as News Reporter.

Jared Whitlock has written for a variety of publications, including The New York Times, WIRED, STAT and the San Diego Union-Tribune. He was a Knight Science journalism fellow at the Massachusetts Institute of Technology and formerly served as a healthcare, biotech and projects reporter at the San Diego Business Journal. As Features Editor, Jared will be writing in-depth reports as well as working with all the writers on staff as Endpoints pursues a broad slate of deep dives on the global biopharma scene.

Aayushi Pratap is coming on board as a News Reporter, and was previously an assistant editor at Forbes, covering healthcare. She also worked as a health reporter in Mumbai, India, with the Hindustan Times, a daily newspaper where she extensively reported on drug resistant infections such as tuberculosis, leprosy and HIV. She has an M.A in Science and Health Journalism from Columbia University. She has an M.Sc in biochemistry and a B.Sc. in zoology. Aayushi has also worked in a molecular and a cell biology laboratory, and won the EurekAlert! 2018 Fellowship for International Science Reporters.

Were thrilled to have Jared and Aayushi join the Endpoints News team at this time of rapid growth. In the last few months, weve expanded and launched several new editorial coverage areas based on subscriber feedback, said John Carroll, Editor & Founder, Endpoints News. With over 145,000 active daily biopharma subscribers and growing, were dedicated to attracting top talent and remaining the top news and analysis destination for biopharma executives globally.

Endpoints is the premier destination for biopharma and life sciences news, and were delighted to welcome two veteran journalists to our editorial team, said Arsalan Arif, Publisher & Founder, Endpoints News. As we continue to expand our news coverage, we are dedicated to ensuring high-quality journalism for our readers.

More here:
Endpoints News Expands Editorial Team With Appointments of Jared Whitlock and Aayushi Pratap - Business Wire

Summer science programs at the library – Bonners Ferry Herald

BONNERS FERRY Science adventures are happening at the Boundary County Library every other Friday.

In 2016 and until COVID-19, the BCL has put on regular science programs. Now they are bringing back video conferences with different zoos and science centers throughout the country.

Many of the summer programs are video conferences and typically a presenter will walk around a zoo with a camera and provide a guided tour and information on the exhibits, said Amy Maggi, science program coordinator for the library.

This allows young learners to travel around the world without leaving the library, she added.

Science programs at the library include craft and coloring pages, which are good ways for kids to develop motor skills. These programs are held year-round with about two events each month, Maggi said.

At the July 8 event, Toledo Zoo's "Venom" live video conference featured a western diamondback rattlesnake and komodo dragon. The guided virtual tour through the zoo featured staff discussing various venomous animals such as sea anemone, cone snail, eyelash viper, pit viper, Goliath birdeater spider, tarantula, scorpion, platypus, and more.

Maggi said that bugs and reptiles are really big with the kids. She said one of her favorite memories of summer science programs was when a python was brought in. About 80 kids were in attendance and got to assist in the handling of the reptile. Kids learned the difference between needed fear and learned fear, she added.

Visual aids are important to grab young learners attention, so any chance Maggi can get she said shell have an animal in the library whether it is a rabbit, turtle or a domesticated animal.

Maggi said she was first inspired to work with animals in Africa after reading a book at the library on volunteering with lions.

So, then I went to Africa and volunteered with lions, she said.

This is also one of the reasons she pulls books on the presentation topics for further reading for participants.

The library still has 70 check-out kits for further learning. The kits include topics of math, science, reading and geography.

The science kits topics include cell biology, a microscope, anatomy, engines, building catapults and much more.

The next upcoming Friday science program is on sea turtle rescues. It will be held July 22 at 10:30 a.m., which is a video conference with Sea Turtle Inc. in Texas.

Coming Aug. 5 Volunteering with Wildlife in Central and South America, presented by Amy Maggi. She has volunteered in Costa Rica, Peru and Ecuador working with animals and conservation efforts.

Read this article:
Summer science programs at the library - Bonners Ferry Herald

Advancing cell therapies – T cells and the combination factor – Marketscreener.com

Please give some background on TC BioPharm and its aims

Kobel: As the global leader in allogeneic gamma delta () T-cell technologies, we are focused on the use of our platform allogeneic T cells from healthy donors as a therapeutic for oncology indications. Right now, we are targeting blood cancers, with clinical data in relapsed/refractory acute myeloid leukaemia (AML), and moving into solid tumours, most likely in some version of a combination therapy or as a modified such as a chimeric antigen receptor (CAR).

Our work is establishing whether it is possible to use allogeneic innate immune cells from a healthy donor to support the immune system of a person with cancer in combatting the condition. It is really the idea of reinforcing nature and letting the immune system do what it was intended to do, which is use this universal, inherent killer to fight diseases.

Why gamma delta T cells?

Kobel: There is no bad cell therapy out there, but all therapies have limitations - there is no such thing as a limitless cell therapy or drug. CAR T-cell therapies, for example, have two: firstly, because they are typically autologous (ie, use a patient's own cells), some patients are simply too sick to be able to donate cells to produce the treatment.

Additionally, CARs target T-cell receptors, and those receptors happen to exist on both healthy and diseased cells, so they can destroy both, causing what is called "onsite off tumour toxicity". This toxicity limits the possible dose that can be given to patients, so it is hard to give a sufficiently large dose to enable the treatment to leave the vasculature and permeate tissues to interact with and fight solid tumours.

T cells are the first line of defence in the immune system to eradicate diseases. They have an inherent ability to seek out and destroy damaged and diseased cells due to the presence of an antigen called isopentenyl pyrophosphate, or IPP for short. All tumours ever discovered and studied emit IPP, while healthy cells do not.

T cells act somewhat like a shark smelling blood; when they sense IPP, the cells slowly make their way towards the concentration until they find the source and affect cell death.

What is beneficial about them is that they have a limited toxicity profile; they have very few side effects, unlike traditional cancer treatments such as chemotherapy. You can also give them to people in conjunction with other drugs because there is no drug-on-drug profile.

Gamma delta T-cell biology

T cells are 'unconventional' T cells and there are relatively few present in peripheral blood. Unlike their better know CD4+ helper T cell and CD8+ cytotoxic T cell cousins, which express alpha beta () T-cell receptors (TCRs), they express TCRs composed of and chains.

In contrast to T cells, the majority of T cells are activated in a major histocompatibility complex (MHC)-independent manner, by both self and non-self ligands. Self ligands that activate T cells in a TCR-dependent manner include IPP, often accumulated by cancer cells, and other markers of cellular stress resulting from infection or tumorigenesis. In response, T cells produce cytokines, chemokines, interact with other immune cells and affect cytolysis of infected or transformed target cells.

As tissue-associated populations of T cells have been identified in the epithelium and mucosa, scientists believe they may serve as the first line of defence against pathogens.

Source: Eberl M, Hayday A. Gamma Delta () T Cells, British Society for Immunology.

For what indications are gamma delta T cells being developed?

Kobel: We are currently in a Phase IIb/III clinical trial for AML using T cells as a second-line therapy, also known as a failed first-line induction. This is a bridge to bone marrow or stem-cell transplant, which is the next step in your standard of care.

The data from our Phase Ib/IIa trial in AML was positive, so we are excited to see if we can replicate these results in other blood cancers, acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL) and multiple myeloma, through some form of an umbrella trial.

I think the way forward for cell therapy is in combining therapies; so not developing monotherapies but instead combining the benefits of two or more treatments, for instance, T cells and checkpoint inhibitors or natural killer (NK) cells

In the Phase Ib/IIa study, the average blast count (measured disease) in patients when they entered the trial was 38 percent; 28 days later, after one dose of T cells, their average blast count had been reduced to six percent, which is borderline remission.

We saw two complete responses including one MLFS or morphological leukaemia-free state, which means they were no longer leukemic. One patient went from a 60 percent blast count to 10 percent within 28 days and another patient lived more than two years after the trial.

These results were really encouraging, especially in patients that were in palliative care - expected to live four to six weeks. We are excited to see what these therapeutics can do in healthier patients, which conceptually should have a better response.

We are also starting to look at solid tumour opportunities in combination with other partners; investigating prostate, pancreatic, colorectal, ovarian and head and neck cancers.

We have developed a costimulatory CAR approach specifically for solid tumours such as ovarian cancer, neuroblastoma and glioblastoma, which is designed to overcome off-tumour toxicity. This is achieved by taking the CAR T-cell receptor and combining it with the T cells' function around IPP. The therapeutic cell expresses both CAR and receptors.

Say the expressed CAR receptor is for CD19; if the CAR binds to a cell expressing CD19 but not IPP, then the receptor does not bind and the therapeutic cell detaches. However, if the cell expresses both CD19 and IPP, and therefore both the CAR and receptors bind, then it completes a biological circuit that kills the cancerous cell. Because of this on-off switch, the damage to healthy cells is minimised and we should therefore be able to dose patients with larger amounts of these CAR T cells safely, allowing them to escape the vasculature and enter tissues to reach tumours in the organs.

How do you envision cell therapies developing in future?

Kobel: Development in the cell therapy landscape is akin to how Ernest Hemingway described going broke; it happens very slowly at first then all of a sudden. Right now, technology is advancing so quickly it is incredible.

Personally, I think the way forward for cell therapy is in combining therapies; so not developing monotherapies but instead combining the benefits of two or more treatments, for instance, T cells and checkpoint inhibitors or natural killer (NK) cells. We believe T cells can form the backbone of these combinations going forwards, given their innate ability within the immune system and their function as tumour killers.

We are very excited by the progress being made in the NK cell arena, as combining allogeneic NK cell infusions with T-cell infusions could be an interesting dynamic. We are of the mindset that you can rebuild, or recreate, the immune system to a certain degree artificially.

Conceptually, you could receive an infusion of T cells, then repeated infusions of NK cells for several weeks before a further T-cell infusion. Repeating this over and over, to the extent that you are basically taking an exogenous version of the immune system, could provide efficacy with limited toxicity.

We also think combining cell therapies with checkpoint inhibitors and bispecific antibodies is interesting, as it could help overcome the iceberg problem. Existing treatments such as checkpoint inhibitors can be limited to accessing the tip of the iceberg when it comes to cancers; they benefit patients with a stable immune system that is able to proliferate immune cells such as T or NK cells. But if you do not have a stable immune system, ie, it is suppressed or compromised, which is the case for the majority of patients, it does not matter how many times you try to invigorate an immune response - the immune system is unable to respond. We are excited to see how combining checkpoint inhibitors and the exogenous infusion of immune cell therapies could benefit patients.

Which challenges must be overcome to continue to advance cell therapies?

Kobel: There is a major bottleneck across all cell therapies and that is supply and demand for the base product of cells. Companies are continually building manufacturing plants to support production, as well as advancing allogeneic technologies to remove certain burdens, both of which are great. However, if we really want to use cell therapies in the way that I believe they can be used, which is not just in oncology but in numerous areas including viral and inflammatory diseases, etc, there are not enough donors to support the potentially vast needs of product creation.

The next step is really developing what we call a "universal donor", which would be induced pluripotent stem cell (iPSC) lines that can produce the requisite cell types, whether they be T cells, NK cells, macrophages or T cells.

We must solve this supply-demand bottleneck, so over the next five to 10 years, I anticipate the removal of the donor entirely and the use of iPSCs as the source for production instead.

Bryan Kobel is the Chief Executive Officer of TC Biopharm and joined the company in June 2021. Bryan has been active in healthcare and life sciences for over 15 years, advising private and public companies on capital structuring and sourcing, and bringing a broad range of investors from private family capital to traditional corporate venture investors to his clients.

TC BioPharm is a publicly-traded (TCBP), clinical-stage cell therapy company developing advanced allogeneic CAR T-cell therapy products for the treatment of cancer, as well as developing gamma delta T-cell therapies for the treatment of infectious disease. The company was established in 2014 and now has five global locations, with its headquarters in Glasgow, Scotland, UK.

About the author

Hannah Balfour is the Science Writer for European Pharmaceutical Review

The post Advancing cell therapies - T cells and the combination factor appeared first on European Pharmaceutical Review.

Russell Publishing Limited, 2022. All Rights Reserved., source Trade Journals

Continue reading here:
Advancing cell therapies - T cells and the combination factor - Marketscreener.com

MIT Engineers Work To Harness the Liver’s Regenerative Abilities To Treat Chronic Disease – SciTechDaily

By tracing the steps of liver regrowth, MIT engineers hope to harness the livers regenerative abilities to help treat chronic disease. Hepatocytes, the one pictured here, are the main functional cells of the liver. Credit: NIH

By tracing the steps of liver regrowth, MIT engineers are striving to harness the livers regenerative abilities to help treat chronic disease.

The human liver has incredible regeneration capabilities: Even if up to 70% of it is removed, the remaining tissue can regrow a full-sized liver in just months.

Being able to take advantage of this regenerative capability could provide doctors with a plethora of options for treating chronic liver disease. MIT engineers have now taken a step toward that goal, by creating a novel liver tissue model that allows them to more precisely trace the steps involved in liver regeneration than has been possible before.

Using the new model can yield information that couldnt be gleaned from studies of mice or other animals, whose biology is not identical to that of humans, says Sangeeta Bhatia, the leader of the research team.

For years, people have been identifying different genes that seem to be involved in mouse liver regeneration, and some of them seem to be important in humans, but they have never managed to figure out all of the cues to make human liver cells proliferate, says Bhatia, the John and Dorothy Wilson Professor of Health Sciences and Technology and of Electrical Engineering and Computer Science at MIT and a member of MITs Koch Institute for Integrative Cancer Research and Institute for Medical Engineering and Science.

The new study, which appears this week in the Proceedings of the National Academy of Sciences, has identified one molecule that appears to play a key role, and also yielded several other candidates that the researchers plan to explore further.

The lead author of the paper is Arnav Chhabra, a former MIT graduate student and postdoctoral researcher.

Most of the patients who need liver transplants suffer from chronic illnesses such as viral hepatitis, fatty liver disease, or cancer. However, if researchers had a reliable way to stimulate the liver to regenerate on its own, some transplants could be avoided, Bhatia says. Or, such stimulation might be used to help a donated liver grow after being transplanted.

From studies in mice, researchers have learned a great deal about some of the regeneration pathways that are activated after liver injury or illness. One key factor is the reciprocal relationship between hepatocytes (the main type of cell found in the liver) and endothelial cells, which line the blood vessels. Hepatocytes produce factors that help blood vessels develop, and endothelial cells generate growth factors that help hepatocytes proliferate.

Another contributor that researchers have identified is fluid flow in the blood vessels. In mice, an increase in blood flow can stimulate the endothelial cells to produce signals that promote regeneration.

Right now when patients come in with liver failure, you have to transplant them because you dont know if theyre going to recover on their own. But if we knew who had a robust regenerative response, and if we just needed to stabilize them for a little while, we could spare those patients from transplant. Sangeeta Bhatia

To model all of these interactions, Bhatias lab teamed up with Christopher Chen, the William F. Warren Distinguished Professor of Biomedical Engineering at Boston University, who designs microfluidic devices with channels that mimic blood vessels. To create these models of regeneration on a chip, the researchers grew blood vessels along one of these microfluidic channels and then added multicellular spheroid aggregates derived from liver cells from human organ donors.

The chip is designed so that molecules such as growth factors can flow between the blood vessels and the liver spheroids. This setup also allows the researchers to easily knock out genes of interest in a specific cell type and then see how it affects the overall system.

Using this system, the researchers showed that increased fluid flow on its own did not stimulate hepatocytes to enter the cell division cycle. However, if they also delivered an inflammatory signal (the cytokine IL-1-beta), hepatocytes did enter the cell cycle.

When that happened, the researchers were able to measure what other factors were being produced. Some were expected based on earlier mouse studies, but others had not been seen before in human cells, including a molecule called prostaglandin E2 (PGE2).

The MIT team found high levels of this molecule, which is also involved in zebrafish regeneration, in their liver regeneration system. By knocking out the gene for PGE2 biosynthesis in endothelial cells, the researchers were able to show that those cells are the source of PGE2, and they also demonstrated that this molecule stimulates human liver cells to enter the cell cycle.

The researchers now plan to further explore some of the other growth factors and molecules that are produced on their chip during liver regeneration.

We can look at the proteins that are being produced and ask, what else on this list has the same pattern as the other molecules that stimulate cell division, but is novel? Bhatia says. We think we can use this to discover new human-specific pathways.

In this study, the researchers focused on molecules that stimulate cells to enter cell division, but they now hope to follow the process further along and identify molecules needed to complete the cell cycle. They also hope to discover the signals that tell the liver when to stop regenerating.

Bhatia hopes that eventually, researchers will be able to harness these molecules to help treat patients with liver failure. Another possibility is that doctors could use such factors as biomarkers to determine how likely it is that a patients liver will regrow on its own.

Right now when patients come in with liver failure, you have to transplant them because you dont know if theyre going to recover on their own. But if we knew who had a robust regenerative response, and if we just needed to stabilize them for a little while, we could spare those patients from transplant, Bhatia says.

Reference: A vascularized model of the human liver mimics regenerative responses by Arnav Chhabra, H.-H. Greco Song, Katarzyna A. Grzelak, William J. Polacheck, Heather E. Fleming, Christopher S. Chen and Sangeeta N. Bhatia, 28 June 2022, Proceedings of the National Academy of Sciences.DOI: 10.1073/pnas.2115867119

The research was funded in part by the National Institutes of Health, the National Science Foundation Graduate Research Fellowship Program, Wellcome Leap, and the Paul and Daisy Soros Fellowship Program.

Excerpt from:
MIT Engineers Work To Harness the Liver's Regenerative Abilities To Treat Chronic Disease - SciTechDaily

p53 in liver cancer: The ultimate betrayal? – Newswise

Newswise Osaka, Japan p53 is one of the most important proteins in cancer biology. Often referred to as a guardian of the genome, p53 becomes activated in response to various cellular stressors like DNA damage. Its activation induces different processes, such as controlled cell death, that prevent cancer development if a cell becomes abnormal. Because of this, p53 mutations are extremely common in cancers, including hepatocellular carcinoma. However, in a recent article published inCancer Research, a team of researchers at Osaka University observed that constant activation of p53 in liver cells of patients suffering from chronic liver disease (CLD) could actually promote the development of liver cancer.

CLD can be brought on by different factors including viruses, alcohol use, and fat accumulation, all of which can induce p53 activation. Previous studies have shown that p53 is in a constant state of activation in the liver cells of CLD patients. Yet, it is not clear what role this plays in CLD pathophysiology.

Clinical data clearly show that p53 is activated in the hepatocytes of individuals with CLD, says Yuki Makino, lead author of the study. Because p53 is such a vital part of how the human body prevents tumor formation, its role in CLD became even more intriguing.

To address their questions, the team generated a mouse model with p53 accumulation in hepatocytes. This was done by deleting Mdm2, the protein responsible for regulating p53 expression by targeting it for degradation. These mice developed liver inflammation with higher amounts of hepatocyte apoptosis and senescence-associated secretory phenotype (SASP), a phenomenon where cells produce signals within the microenvironment that can cause nearby cells to become cancerous. In fact, mice with p53 accumulation did have increased liver tumor development.

We also observed an expanded population of hepatic progenitor cells (HPCs), which have stem cell-like characteristics, explains senior author Tetsuo Takehara. When the HPCs were isolated, grown in culture, and then injected under the skin of lab mice, these animals developed tumors. This suggested that HPCs played a key part in the liver tumor formation seen in the animals with p53 accumulation.

Interestingly, acceleration of liver tumor development and the other observed phenotypes did not occur when p53 was deleted in addition to Mdm2 in the hepatocytes. These results demonstrated the significance of constant p53 activity in the tumorigenesis.

We then compared samples from 182 CLD patients with 23 healthy liver samples, says Dr. Makino. The CLD liver biopsy samples showed activated p53 was positively correlated with apoptosis levels, SASP, HPC-associated gene expression, and later cancer development.

The authors concluded that constitutively activated p53 in hepatocytes of CLD patients can create a microenvironment that is supportive of tumor formation from HPCs. Their work proposes a novel and paradoxical mechanism of liver tumorigenesis because p53 is one of the most well-known tumor suppressor genes. These data could highlight p53 as a potential cancer-prevention treatment target for CLD patients.

###

The article, Constitutive activation of the tumor suppressor p53 in hepatocytes paradoxically promotes non-cell autonomous liver carcinogenesis, was published inCancer Researchat DOI:https://doi.org/10.1158/0008-5472.CAN-21-4390

About Osaka University

Osaka University was founded in 1931 as one of the seven imperial universities of Japan and is now one of Japan's leading comprehensive universities with a broad disciplinary spectrum. This strength is coupled with a singular drive for innovation that extends throughout the scientific process, from fundamental research to the creation of applied technology with positive economic impacts. Its commitment to innovation has been recognized in Japan and around the world, being named Japan's most innovative university in 2015 (Reuters 2015 Top 100) and one of the most innovative institutions in the world in 2017 (Innovative Universities and the Nature Index Innovation 2017). Now, Osaka University is leveraging its role as a Designated National University Corporation selected by the Ministry of Education, Culture, Sports, Science and Technology to contribute to innovation for human welfare, sustainable development of society, and social transformation.

Website:https://resou.osaka-u.ac.jp/en

The rest is here:
p53 in liver cancer: The ultimate betrayal? - Newswise

Heated Debate Persists over the Origins of Complex Cells – Scientific American

For billions of years after the origin of life, the only living things on Earth were tiny, primitive cells resembling todays bacteria. But then, more than 1.5 billion years ago, something remarkable happened: One of those primitive cells, belonging to a group known as the archaea, swallowed another, different one a bacterium.

Instead of being digested, the bacterium took up permanent residence within the other organism as what biologists call an endosymbiont. Eventually, it integrated fully into its archaeal host cell, becoming what we know today as the mitochondrion, the crucial energy-producing component of the cell.

Its acquisition has long been viewed as the key step in what is arguably the most important evolutionary leap since the origin of life itself: the transition from early primitive cells, or prokaryotes, to the more sophisticated cells of higher organisms, or eukaryotes, including ourselves.

Its a neat story youll find in most biology textbooks but is it quite that simple? In the last few years, new evidence has challenged the notion that mitochondria played a seminal role in this transition. Researchers sequencing the genomes of modern-day relatives of the first eukaryotes have found many unexpected genes that dont seem to come from either the host or the endosymbiont. And that, some scientists suggest, might mean that the evolution of the first eukaryotes involved more than two partners and happened more gradually than suspected.

Others dont see a reason yet to abandon the theory that the acquisition of the mitochondrion was the spark that ignited the rapid evolution of eukaryotes giving rise, eons later, to plants, animals, vertebrates, ourselves. Fresh evidence from genomics and cell biology may help resolve the debate, while also pointing to knowledge gaps that still need to be filled to understand one of the foundational events in our own ancestry, the origin of complex cells.

Uncertainties arose when mystery genes turned up in the last decade when researchers including Toni Gabaldn, an evolutionary genomicist at the Barcelona Supercomputing Centre, and his colleagues took advantage of todays cheap gene sequencing technology to explore the genomes of a wide range of eukaryotes, including several obscure, primitive, modern-day relatives of early eukaryotes.

They expected to find genes whose lineage traced back to either the archaeal host or the mitochondrial ancestor, a member of a group called the alphaproteobacteria. But to their surprise, the scientists also found genes that seemed to come from a wide range of other bacteria. Gabaldn and colleagues hypothesized that the cellular ancestor of eukaryotes had acquired the genes from a variety of partners. Those partners could have been additional endosymbionts that were later lost, or free-living bacteria that passed one or a few of their genes to the ancestral host in a common process called horizontal gene transfer. Either way, the tango that led to eukaryotes involved more than two dancers, they suggested.

It is clear now that there are additional contributions from additional partners, says Gabaldn, who wrote about the early evolution of eukaryotes in the 2021 Annual Review of Microbiology.

Its tough to know exactly where those ancient foreign genes came from because so much time has elapsed. But there are many more recent, looser endosymbioses where the origin of foreign genes is easier to identify, says John McCutcheon, an evolutionary cell biologist at Arizona State University in Tempe who wrote about endosymbiont evolution in the 2021 Annual Review of Cell and Developmental Biology. Studying these might, by analogy, give us a shot at understanding how mitochondria and the first eukaryotes could have evolved, he says.

A prime example is a roughly 100-million-year-old partnership between insects called mealybugs and two bacterial endosymbionts, one nested inside the other in the mealybugs cells. (The endosymbionts make essential amino acids that the mealybug cant get from its diet.) Based on a genomic analysis, McCutcheon and his colleagues found that the mealybugs metabolic pathways are now a mosaic made up of genes that originated with the bugs themselves, came in with their endosymbionts or were picked up by horizontal transfer from other microbes in the environment. To make this work, McCutcheons team showed, mealybug cells had to evolve an apparatus that transports proteins to and fro between what were once independent organisms allowing ones from the mealybug cell nucleus to journey across two sets of endosymbiont membranes for use by the innermost endosymbiont

Something similar occurs in a single-celled, amoeba-like eukaryote called Paulinella. Paulinella has an endosymbiont, engulfed tens of millions of years ago, that allows it to harvest energy from sunlight without the chloroplast organelles that usually power photosynthesis. Eva Nowack, who leads a lab at the University of Dusseldorf in Germany, discovered that Paulinelllas genome now contains genes from the endosymbiont along with others that were acquired through horizontal gene transfer.

Remarkably, the endosymbiont imports more than 400 proteins from the host nucleus, so it also must have evolved a complicated protein transport system like the mealybugs. Thats quite exciting, says molecular evolutionist Andrew Roger, who studies the evolution of organelles at Dalhousie University in Halifax, Canada, because it suggests that evolving these transport systems anew isnt as difficult as previously thought.

These examples illustrate how endosymbionts become integrated with their hosts and suggest that horizontal gene transfers from various sources could have been quite frequent early in the evolution of eukaryotes, too. It doesnt show that is what happened in the formation of the mitochondria, but it shows that its possible, says McCutcheon.

Others agree. Theres lots of strong evidence for horizontal gene transfer in eukaryotes, so theres really no reason to say that it couldnt have happened during that period of the prokaryote-eukaryote transition. In fact, it almost certainly did happen, Roger says.

The implication is that the ancient host could have gradually acquired eukaryotic traits one at a time, like a shopper picking up items in a shopping bag, via horizontal gene transfers or by gobbling a series of endosymbionts, explains John Archibald, a comparative genomicist at Dalhousie University. Some of those newly acquired genes could have been useful to the host as it evolved the rest of the machinery found in modern eukaryotic cells.

If so, by the time the ancient host engulfed the precursor of mitochondria, it would have already possessed many eukaryotic features, perhaps including some organelles, the internal compartments surrounded by membranes meaning that mitochondria would have been not the main driver of eukaryotic evolution but a late addition.

But despite all the evidence supporting a gradualist hypothesis for the evolution of eukaryotes, there are some reasons for doubt. The first is that these more recent endosymbioses may not tell us much about what happened during the origin of eukaryotes after all, in these cases the modern host cells were already eukaryotes. These examples tell us how easy it is, once you have a eukaryotic cell, to establish intracellular endosymbioses, says Bill Martin, an evolutionary biologist who studies the origins of eukaryotes at the University of Dusseldorf. But eukaryotes already have all the intracellular machinery needed to engulf another cell. Its not at all clear that the ancestral proto-eukaryote had that ability, Martin says which would make the barrier to that first endosymbiosis much higher. That, to him, argues against a gradual evolution of the eukaryotic cell.

In fact, some evidence suggests that key eukaryotic features were acquired all at once, rather than gradually. All eukaryotes have the exact same set of organelles familiar to anyone who has studied cell biology: nucleus, nucleolus, ribosomes, rough and smooth endoplasmic reticulum, Golgi apparatus, cytoskeleton, lysosome and centriole. (Plants and a few other photosynthetic eukaryotes have one extra, the chloroplast, which everyone agrees arose through a separate endosymbiosis.) That strongly suggests the other cellular components all originated at about the same time if they didnt, different eukaryotic lineages ought to have different mixes of organelles, says Jennifer Lippincott-Schwartz, a cell biologist at the Howard Hughes Medical Institutes Janelia Research Campus in Virginia.

Some biochemical evidence points that way, too. The ancestral host and endosymbiont belonged to different branches of the tree of life archaea and bacteria, respectively that use different molecules to build their membranes. None of the membranes of eukaryotic organelles are exclusively archaeal in structure, so its unlikely they came from the ancestral host cell. Instead, this suggests that the archaeal host was a relatively simple cell that evolved its other organelles only after the arrival of the mitochondrial ancestor.

But what about all those mysterious foreign genes recently found in the eukaryotic family tree? Theres another possible explanation, Martin says. All those foreign genes could have arrived in a single package with the endosymbiont that evolved into the mitochondrion. Later in the 1.5 billion years following that event those genes could have been scattered among many bacterial groups, courtesy of the ease with which bacteria swap genes to and fro. That would give the erroneous impression that multiple partners contributed genes to the early eukaryote.

Moreover, Martin adds, if the gradualist idea is correct, different lineages of eukaryotes should have fundamentally and measurably different collections of genes, but he has shown they do not. There is no evidence to suggest that there were serial acquisitions, Martin says. A single acquisition of mitochondria at the origin of eukaryotes is enough.

The debate is unlikely to be settled soon. Its very hard to find data thats going to make us clearly distinguish between these alternatives, says Roger. But if further studies of obscure, primitive eukaryotes revealed some that have only a subset of eukaryotic organelles, this could lend weight to the gradualist hypothesis. On the other hand, if evidence was found for a way that a simple archaeal cell could acquire an endosymbiont, that would make the mitochondria early hypothesis more plausible.

People are drawn to big questions, and the harder they are to answer, the more people are drawn to them and debate them, says Archibald. Thats what makes it fun.

This article originally appeared in Knowable Magazine, an independent journalistic endeavor from Annual Reviews. Sign up for the newsletter.

The rest is here:
Heated Debate Persists over the Origins of Complex Cells - Scientific American

Lect/Assist Prof in Plant Cell Biology & Biotech job with UNIVERSITY COLLEGE DUBLIN (UCD) | 297237 – Times Higher Education

Applications are invited for a Temporary post of a Lecturer / Assistant Professor in Plant Cell Biology and Biotechnology within UCD School of Biology & Environmental Biology

The School of Biology & Environmental Science at University College Dublin is seeking to appoint a Lecturer (Above the Bar) in Plant Cell Biology and Biotechnology.

The School offers a diverse portfolio of programmes at both undergraduate and postgraduate levels, including BSc degrees in Cell and Molecular Biology, Plant Biology, Zoology, Environmental Biology and Genetics, and MSc degrees in Plant Biology, Applied Environmental Science, Environmental Sustainability, Global Change and Biological & Biomolecular Science (by negotiated learning).

We are looking for a candidate who has a demonstrated passion for student engagement and teaching and will join a team within the School delivering lectures in the broad area of plant cell biology and biotechnology. The purpose of this post is to provide undergraduate teaching (and associated administrative tasks) covering general aspects of plant cell and molecular biology, within plant, animal and fungal kingdoms. The successful candidate would also be expected to contribute to the supervision of final year and MSc project students and participate in the scholarly activities of the School where appropriate. The candidate should complement and engage with current academic staff and research programmes within the School and wider UCD community Candidates should have a PhD in an appropriate discipline and alongside their teaching and administration duties, will have the opportunity to develop their own research agenda. The School has central facilities enabling plant cell and tissue culture, molecular biology and extensive greenhouse space and state of the art climate control chambers. The successful applicant will be afforded laboratory space and will be supported in developing their research programme

95 Lecturer / Assistant Professor Above the Bar salary scale: 55,951 - 88,601 per annumAppointment will be made on the appropriate scale in accordance with UCD and Department of Finance guidelines.

Closing date: 17:00hrs (local Irish time) on 14th July 2022

Applications must be submitted by the closing date and time specified. Any applications which are still in progress at the closing time of 17:00hrs (Local Irish Time) on the specified closing date will be cancelled automatically by the system. UCD are unable to accept late applications.

UCD do not require assistance from Recruitment Agencies. Any CV's submitted by Recruitment Agencies will be returned.

Note: Hours of work for academic staff are those as prescribed under Public Service Agreements. For further information please follow link below: https://www.ucd.ie/hr/t4media/Academic Contract.pdf. Prior to application, further information (including application procedure) should be obtained from the Work at UCD website: https://www.ucd.ie/workatucd/jobs/

Read more:
Lect/Assist Prof in Plant Cell Biology & Biotech job with UNIVERSITY COLLEGE DUBLIN (UCD) | 297237 - Times Higher Education